Who Should Not Consume Mad Honey: Contraindications Based on Clinical Evidence

How GTX Creates Risk: Mechanism Summary

Grayanotoxin binds to voltage-gated sodium channels and holds them in the open (active) state, preventing normal repolarisation. In cardiac tissue, this produces: slowed sinoatrial (SA) node firing leading to bradycardia; delayed atrioventricular (AV) node conduction leading to AV block in severe cases; and reduced cardiac output leading to hypotension.

Any pre-existing condition that already compromises cardiac conduction, autonomic regulation, or cardiovascular reserve creates an additive risk when GTX is introduced.

Absolute Contraindications

The following conditions are associated with a serious risk of adverse cardiovascular events based on available clinical evidence and pharmacological reasoning:

1. Known Bradycardia (Resting Heart Rate Chronically Below 60 BPM)

GTX’s primary cardiovascular effect is further reduction in heart rate via SA node suppression. Individuals with existing bradycardia have reduced functional reserve; GTX-induced further slowing can cause haemodynamic compromise at doses that would produce only mild effects in individuals with a normal baseline heart rate. Multiple published cases document patients with resting bradycardia requiring emergency atropine after even moderate mad honey exposure.

2. Sick Sinus Syndrome (SSS) / Sinus Node Dysfunction

SSS is a condition in which the SA node already fails to reliably regulate heart rate. GTX’s suppressive effect on SA node firing represents a direct mechanism of risk in these individuals.

3. Any Degree of AV Block (First-, Second-, or Third-Degree)

GTX slows AV node conduction. In individuals with existing AV block, even partial additional AV nodal suppression can progress to complete heart block — a condition requiring emergency intervention. Published case reports of GTX-induced complete AV block uniformly describe patients with either pre-existing AV disease or very high-dose exposures.

4. Wolff-Parkinson-White (WPW) Syndrome

WPW involves an abnormal electrical pathway in the heart. Agents that suppress normal AV conduction (as GTX does) can paradoxically accelerate conduction through accessory pathways, creating risk of ventricular arrhythmia.

5. Heart Failure (Any Ejection Fraction Class)

Heart failure reduces cardiac reserve. GTX-induced reductions in heart rate and systemic vascular tone can precipitate acute decompensation in individuals who depend on compensatory mechanisms to maintain adequate cardiac output.

6. Recent Cardiac Surgery or Implanted Cardiac Device (Pacemaker, ICD)

Post-operative cardiac tissue has altered electrophysiological properties. Pacemakers are set to respond to rate changes; GTX-induced bradycardia may trigger pacing responses or interfere with device thresholds in unpredictable ways. No published data exists on GTX exposure in pacemaker patients specifically.

High-Concern Populations

Elderly Individuals

EFSA’s 2023 risk assessment specifically identified elderly individuals as a higher-concern population, citing reduced physiological reserve, higher prevalence of underlying cardiovascular conditions, and more frequent polypharmacy that may interact with GTX. Published Turkish case data show that older patients in mad honey intoxication series experienced more severe cardiovascular outcomes and longer hospital stays than younger patients with comparable exposure.

Children and Adolescents

EFSA identified children as a high-concern group based on body weight-adjusted exposure: a child consuming the same quantity of honey as an adult receives a substantially higher dose in mg/kg body weight terms. No safe consumption threshold has been established for any age group, and children’s cardiovascular systems may have lower tolerance for the bradycardic and hypotensive effects of GTX.

Individuals with Autonomic Dysfunction

Conditions, including diabetic autonomic neuropathy, Parkinson’s disease-related autonomic failure, and postural orthostatic tachycardia syndrome (POTS), affect the autonomic nervous system’s ability to compensate for hypotension and heart rate changes. GTX challenges both parameters; individuals with impaired autonomic compensation may experience more severe and prolonged haemodynamic effects.

Individuals on Cardiovascular Medications

Multiple medication classes have pharmacological interactions with GTX. This is covered in detail in SS-06. In brief, beta-blockers, calcium channel blockers, digoxin, and antiarrhythmic agents all create an additive or synergistic risk of bradycardia and hypotension when combined with GTX.

Areas of Insufficient Data — Precautionary Avoidance Recommended

The following conditions lack published clinical data specific to mad honey or GTX. In the absence of safety data, precautionary avoidance is appropriate:

• Pregnancy: No published research has assessed GTX exposure during pregnancy in humans. Animal models of sodium channel activation during fetal development raise theoretical concerns. Additionally, the haemodynamic changes of pregnancy may alter GTX pharmacokinetics.
• Breastfeeding: GTX transfer into human breast milk has not been studied. Given the molecular size and lipid-soluble properties of diterpenoids, transfer is pharmacologically plausible. Precautionary avoidance is appropriate given the cardiovascular sensitivity of infants.
• Epilepsy and Seizure Disorders: GTX’s effects on voltage-gated sodium channels — the same class targeted by many antiepileptic drugs — raise theoretical concerns about interactions with sodium channel-targeted antiepileptics (carbamazepine, lamotrigine, phenytoin). No published human data exists.
• Renal Impairment: GTX clearance pathways are not fully characterised in humans. If renal excretion contributes meaningfully to GTX elimination, individuals with impaired kidney function may experience prolonged exposure at a given dose. EFSA’s 2023 assessment noted this as a data gap.
• Thyroid Disease: Hypothyroidism is associated with baseline bradycardia; hyperthyroidism with tachycardia. Both conditions alter cardiac sensitivity to rate-modulating agents. GTX’s bradycardic effect in the context of hypothyroid-related baseline bradycardia creates additive concern.

A Note on Self-Assessment

Several of the contraindications above — particularly first-degree AV block, mild sick sinus syndrome, and early heart failure — may be present without the individual being aware. A resting ECG and baseline cardiovascular assessment by a physician is the only reliable method to rule out structural contraindications.

Consumer heart rate and blood pressure apps do not provide sufficient data to rule out AV conduction abnormalities. If you are uncertain about your cardiovascular status, consult a healthcare provider before considering mad honey consumption.

Sources

1. Jansen SA, et al. (2012). Grayanotoxin poisoning: ‘mad honey disease’ and beyond. Cardiovascular Toxicology, 12(3), 208–215.  https://pmc.ncbi.nlm.nih.gov/articles/PMC3404272/
2. EFSA CONTAM Panel (2023). Risks for human health related to the presence of grayanotoxins in certain honey. EFSA Journal, 21(3), e7866.  https://doi.org/10.2903/j.efsa.2023.7866
3. Biberoglu S, et al. (2013). Mad honey poisoning.  https://pmc.ncbi.nlm.nih.gov/articles/PMC3658790/
4. Koca I, et al. (2015). Grayanotoxin — ongoing consumption after poisoning.  https://pmc.ncbi.nlm.nih.gov/articles/PMC4115918/
5. Aryal N, et al. (2025). Grayanotoxins in mad honey: mechanisms of toxicity, clinical management, and therapeutic implications. Journal of Applied Toxicology.  https://doi.org/10.1002/jat.4855

NEXT READS

1. Mad Honey and Medication Interactions: What the Research Shows
2. Emergency Response: Recognising and Responding to Mad Honey Adverse Effects